寡合性氨酸氨酸可以通过ITGA3介导途径逆转肝细胞癌中伦瓦替尼布抗性
Takayuki Noma1,2, Yuan Li1,3, Yuma Wada2
1Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, CA 91016, USA.
Pharmaceuticals (Basel, Switzerland)
|September 27, 2025
概括
寡合性益阳氨酸 (OPCs) 可以克服肝细胞癌 (HCC) 中的伦瓦替尼布耐药性. 这种天然化合物组合疗法向整合素通路,增强抗瘤效果和耐药HCC细胞的亡.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 肝细胞癌 (HCC) 构成一个重大的全球健康挑战,由于获得的耐药性,伦瓦提尼布治疗往往失败.
- 寡合性益氨酸 (OPCs),天然多,表现出抗瘤特性,并研究其对抗药物耐药性的潜力.
- 这项研究侧重于OPCs作为一种克服HCC.Lenvatinib耐药性的策略.
研究的目的:
- 研究OPCs在克服HCC.Lenvatinib耐药性的有效性.
- 为了确定分子机制和信号通路涉及伦瓦丁尼布耐药性.
- 评估OPCs作为对抗性HCC的潜在辅助疗法.
主要方法:
- 已确立的伦瓦替尼布抗性HCC细胞系 (Huh-7和PLC-PRF-5).
- 进行了系统的细胞培养实验,以评估抗瘤效果.
- 利用全基因组的转录基因组分析,网络药理学和途径丰富分析.
主要成果:
- 与伦瓦替尼布结合的OPCs在耐药HCC细胞中显示出显著的协同抗增殖效应 (Bliss协同效应> 10).
- ITGA3被确定为伦瓦丁尼布耐药性和阿诺基斯耐药性的关键因素.
- 组合疗法抑制了ITGA3-EGFR-AKT信号传递,恢复了阿诺基斯的敏感性,减少了球形状的形成,并增加了亡.
结论:
- 通过向整蛋白通路,OPCs可以克服HCC中的化疗耐药性.
- 这项研究提供了OPCs针对整合素途径克服化学抵抗的第一个证据.
- OPCs显示出作为抗化疗耐药HCC的辅助疗法的潜力.
关键词:
在ITGA3中,ITGA3是指ITGA3中,ITGA3是指ITGA3.一个年轻的ikis anoikis肝细胞癌是肝细胞癌.伦瓦提尼布耐药性 伦瓦提尼布耐药性一些寡头类的proanthocyanidins.有协同效应的效应.更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
665
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K